Acute myeloid leukemia.
Acute myeloid leukemia (AML) is a heterogeneous group of leukemias that result from clonal transformation of hematopoietic precursors through the acquisition of chromosomal rearrangements and multiple gene mutations. As a result of highly collaborative clinical research by pediatric cooperative cancer groups worldwide, disease-free survival has improved significantly during the past 3 decades. Further improvements in outcomes of children who have AML probably will reflect continued progress in understanding the biology of AML and the concomitant development of new molecularly targeted agents for use in combination with conventional chemotherapy drugs.
Rubnitz
Jeffrey E
JE
Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA. jeffrey.rubnitz@stjude.org
Gibson
Brenda
B
Smith
Franklin O
FO
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms; D002648:Child; D002999:Clone Cells / Q000473:pathology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D016896:Treatment Outcome
D000970:Antineoplastic Agents